FR2931677B1 - Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs - Google Patents

Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs

Info

Publication number
FR2931677B1
FR2931677B1 FR0802996A FR0802996A FR2931677B1 FR 2931677 B1 FR2931677 B1 FR 2931677B1 FR 0802996 A FR0802996 A FR 0802996A FR 0802996 A FR0802996 A FR 0802996A FR 2931677 B1 FR2931677 B1 FR 2931677B1
Authority
FR
France
Prior art keywords
association
treatment
composition containing
same
receptor agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0802996A
Other languages
English (en)
Other versions
FR2931677A1 (fr
Inventor
Olivier Bergis
Philippe Pichat
Alexandre Urani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0802996A priority Critical patent/FR2931677B1/fr
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to AU2009264016A priority patent/AU2009264016B2/en
Priority to BRPI0913236A priority patent/BRPI0913236A2/pt
Priority to KR1020107029081A priority patent/KR20110021946A/ko
Priority to CN2009801204747A priority patent/CN102046164B/zh
Priority to RU2010154417/15A priority patent/RU2493851C2/ru
Priority to CA2726291A priority patent/CA2726291A1/fr
Priority to PCT/FR2009/051041 priority patent/WO2009156680A2/fr
Priority to MX2010013241A priority patent/MX2010013241A/es
Priority to EP09769521A priority patent/EP2293790A2/fr
Priority to JP2011512185A priority patent/JP2011522017A/ja
Priority to SG2013041421A priority patent/SG191623A1/en
Publication of FR2931677A1 publication Critical patent/FR2931677A1/fr
Application granted granted Critical
Publication of FR2931677B1 publication Critical patent/FR2931677B1/fr
Priority to IL209601A priority patent/IL209601A0/en
Priority to US12/958,025 priority patent/US20110136791A1/en
Priority to HK11110041.5A priority patent/HK1155943A1/xx
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
FR0802996A 2008-06-02 2008-06-02 Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs Expired - Fee Related FR2931677B1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
FR0802996A FR2931677B1 (fr) 2008-06-02 2008-06-02 Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
JP2011512185A JP2011522017A (ja) 2008-06-02 2009-06-02 ニコチン受容体の部分アゴニストとアセチルコリンエステラーゼ阻害剤との組み合わせ、これらを含有する医薬組成物、および認知障害の処置におけるこれらの使用
KR1020107029081A KR20110021946A (ko) 2008-06-02 2009-06-02 니코틴 수용체 부분 효능제와 아세틸콜린에스테라제 억제제의 조합물, 이를 함유하는 제약 조성물, 및 인지 장애를 치료하는 데에 있어서의 그의 용도
CN2009801204747A CN102046164B (zh) 2008-06-02 2009-06-02 烟碱性受体部分激动剂和乙酰胆碱酯酶抑制剂的组合、含有所述组合的药物组合物及其在治疗认知障碍中的用途
RU2010154417/15A RU2493851C2 (ru) 2008-06-02 2009-06-02 Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинестеразы, содержащая ее фармацевтическая композиция и ее применение в лечении когнитивных расстройств
CA2726291A CA2726291A1 (fr) 2008-06-02 2009-06-02 Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition pharmaceutique la contenant et son utilisation dans le traitement des troubles cognitifs
PCT/FR2009/051041 WO2009156680A2 (fr) 2008-06-02 2009-06-02 Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition pharmaceutique la contenant et son utilisation dans le traitement des troubles cognitifs
MX2010013241A MX2010013241A (es) 2008-06-02 2009-06-02 Asociacion de un agonista parcial de los receptores nicotinicos y de un inhibidor de la acetilcolinesterasa, composicion farmaceutica que la contiene y su uso en el tratamiento de los trastornos cognitivos.
AU2009264016A AU2009264016B2 (en) 2008-06-02 2009-06-02 Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
BRPI0913236A BRPI0913236A2 (pt) 2008-06-02 2009-06-02 associação de um agonista parcial dos receptores nicotínicos e de um inibidor de acetilcolinesterase, composição farmacêutica que a contém e a respectiva utilização no tratamento dos distúrbios cognitivos
SG2013041421A SG191623A1 (en) 2008-06-02 2009-06-02 Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
EP09769521A EP2293790A2 (fr) 2008-06-02 2009-06-02 Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition pharmaceutique la contenant et son utilisation dans le traitement des troubles cognitifs
IL209601A IL209601A0 (en) 2008-06-02 2010-11-28 Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
US12/958,025 US20110136791A1 (en) 2008-06-02 2010-12-01 Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
HK11110041.5A HK1155943A1 (en) 2008-06-02 2011-09-23 Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0802996A FR2931677B1 (fr) 2008-06-02 2008-06-02 Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs

Publications (2)

Publication Number Publication Date
FR2931677A1 FR2931677A1 (fr) 2009-12-04
FR2931677B1 true FR2931677B1 (fr) 2010-08-20

Family

ID=40229706

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0802996A Expired - Fee Related FR2931677B1 (fr) 2008-06-02 2008-06-02 Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs

Country Status (15)

Country Link
US (1) US20110136791A1 (fr)
EP (1) EP2293790A2 (fr)
JP (1) JP2011522017A (fr)
KR (1) KR20110021946A (fr)
CN (1) CN102046164B (fr)
AU (1) AU2009264016B2 (fr)
BR (1) BRPI0913236A2 (fr)
CA (1) CA2726291A1 (fr)
FR (1) FR2931677B1 (fr)
HK (1) HK1155943A1 (fr)
IL (1) IL209601A0 (fr)
MX (1) MX2010013241A (fr)
RU (1) RU2493851C2 (fr)
SG (1) SG191623A1 (fr)
WO (1) WO2009156680A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
NZ707955A (en) 2010-09-23 2016-03-31 Abbvie Bahamas Ltd Monohydrate of an azaadamantane derivative
EP2836795B1 (fr) 2012-04-14 2018-03-14 Audi AG Procédé, système et véhicule pour effectuer un voyage en groupe
CN103333163A (zh) * 2013-07-09 2013-10-02 广州中医药大学 一种苯并呋喃类衍生物及其制备方法和应用
DK3200828T3 (da) * 2014-10-03 2020-10-12 Lachesis Biosciences Ltd Intranasale sammensætninger til behandling af neurologiske og neurodegenerative sygdomme og forstyrrelser
RU2624978C2 (ru) * 2015-07-27 2017-07-11 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ лечения умеренного когнитивного снижения

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID27504A (id) * 1998-10-01 2001-04-12 Novartis Ag Formulasi oral baru
FR2791678B1 (fr) * 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
US20010036949A1 (en) * 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
ES2275808T3 (es) * 2001-02-06 2007-06-16 Pfizer Products Inc. Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos.
KR100861466B1 (ko) * 2001-04-24 2008-10-02 메르크 파텐트 게엠베하 항혈관형성제 및 ＴＮＦα를 이용한 병용 요법
WO2004037234A2 (fr) * 2002-10-24 2004-05-06 Merz Pharma Gmbh & Co. Kgaa Therapie combinee faisant appel a des derives de 1-aminocyclohexane ainsi qu'a des inhibiteurs d'acetylcholinesterase
BR0317110A (pt) * 2002-12-11 2005-10-25 Pharmacia & Upjohn Co Llc Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
DK1641454T3 (da) * 2003-06-27 2009-02-09 Pfizer Prod Inc Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
CA2554600A1 (fr) * 2004-01-26 2005-08-11 Cortex Pharmaceuticals Inc. Renforcement de la facilitation induite par ampakine des reponses synaptiques par les inhibiteurs de la cholinesterase
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
KR20070015607A (ko) * 2004-05-07 2007-02-05 메모리 파마슈티칼스 코포레이션 1ｈ-인다졸, 벤조티아졸, 1,2-벤조이속사졸,1,2-벤조이소티아졸, 및 크로몬 및 그의 제조법 및 용도
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
WO2007093600A1 (fr) * 2006-02-14 2007-08-23 Neurosearch A/S Nouveaux dérivés de diazabicycloalkane et leur utilisation médicale
EP2083921A2 (fr) * 2006-09-04 2009-08-05 Neurosearch A/S Combinaisons pharmaceutiques contenant un modulateur du recepteur de la nicotine et un facilitateur cognitif
KR101122469B1 (ko) * 2007-04-02 2012-07-12 파킨슨즈 인스티튜트 처치 치료의 부작용을 감소시키기 위한 방법 및 조성물
JP5383788B2 (ja) * 2008-03-19 2014-01-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ニコチン性アセチルコリン受容体モジュレーターとしての三置換された１，２，４−トリアゾール
AU2009245715B2 (en) * 2008-05-09 2014-01-09 Janssen Pharmaceutica Nv Trisubstituted pyrazoles as acetylcholine receptor modulators

Also Published As

Publication number Publication date
JP2011522017A (ja) 2011-07-28
WO2009156680A2 (fr) 2009-12-30
RU2010154417A (ru) 2012-07-20
EP2293790A2 (fr) 2011-03-16
IL209601A0 (en) 2011-02-28
WO2009156680A3 (fr) 2010-04-22
CA2726291A1 (fr) 2009-12-30
US20110136791A1 (en) 2011-06-09
BRPI0913236A2 (pt) 2016-01-19
CN102046164B (zh) 2013-02-20
SG191623A1 (en) 2013-07-31
KR20110021946A (ko) 2011-03-04
RU2493851C2 (ru) 2013-09-27
AU2009264016A1 (en) 2009-12-30
FR2931677A1 (fr) 2009-12-04
CN102046164A (zh) 2011-05-04
AU2009264016B2 (en) 2014-09-11
MX2010013241A (es) 2011-01-21
HK1155943A1 (en) 2012-06-01

Similar Documents

Publication Publication Date Title
FR2931677B1 (fr) Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
FR2895676B1 (fr) Composition cosmetique contenant de la glaucine et son utilisation
MA28512B1 (fr) Derive heterocyclique accole, composition medicamenteuse en contenant, et son utilisation medicamenteuse
MA32627B1 (fr) Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase
BRPI0817051A2 (pt) "respirador com peça facial filtrante"
GB2434604B (en) Porous composites containing hydrocarbon-soluble well treatment agents and methods for using the same
SI2176252T1 (sl) 2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema
IL179674A0 (en) Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
SG163518A1 (en) Amido compounds and their use as pharmaceuticals
ME02333B (me) FARMACEUTSKE SMEŠE KOJE SADRŽE AKTIVIN-ActRIIA ANTAGONISTE I NJIHOVA UPOTREBA U PREVENCIJI ILI LEČENJU MULTIPLOG MIJELOMA
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
FR2925522B1 (fr) Procede de traitement superficiel d'un alliage de zirconium ou de hafnium, et piece ainsi traitee
MA32686B1 (fr) Composés, compositions et procédés pour le traitement de maladies de la b-amyloïde et de synucléinopathies
EP1812037A4 (fr) Alcynes de cyclosporine, et leur utilite comme agents pharmaceutiques
MA29030B1 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
MA29084B1 (fr) Derives d'indenyle et leur utilisation dans le traitement de troubles neurologiques
FR2917622B1 (fr) Utilisation d'un antagoniste par1 dans le traitement de la fibrillation atriale.
EP2134863A4 (fr) Modifications génétiques sur le chromosome 16 et procédés d'utilisation de celles-ci pour le diagnostic et le traitement du diabète de type i
FR2919187B1 (fr) Utilisation d'ecorces de levure pour le traitement et/ou la prevention de l'hyperinsulinemie.
IL197876A0 (en) N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
FR2902326B1 (fr) Utilisation de la coumarine, de butylated hydroxyanisole et d'ethoxyquine pour le traitement de la canitie
FR2937251B1 (fr) Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil
DE502007002185D1 (de) Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
FR2920301B1 (fr) Utilisation d'une association hesperidine et microorganisme pour le traitement de la secheresse des matieres keratiniques.
ZA200808463B (en) Use of combination preparations containing thrombin receptor antagonists for treating cardiovascular disorders

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20150227